Ergomed

Ergomed is a publicly traded, UK-headquartered provider of specialized drug development services, operating globally since 1997. The company has built a strong reputation by focusing on the needs of small to mid-sized biopharma clients, particularly in complex and high-need therapeutic areas such as oncology and rare diseases. Its strategy is centered on offering an integrated suite of services—clinical research (CRO), pharmacovigilance (PrimeVigilance), and GxP compliance (ADAMAS Consulting)—enabling it to support clients from early development through post-marketing. A history of strategic acquisitions has fueled its growth and geographic expansion, solidifying its position as a nimble and expert-driven partner in the global CRO landscape.

Ergomed's platform is an integrated service delivery framework combining deep therapeutic expertise in complex trials, specialized pharmacovigilance processes, and regulatory compliance auditing, supported by enterprise technology systems for clinical trial and safety data management.

Ergomed competes with mid-sized and large global CROs (e.g., ICON, Medpace) in clinical research, specialized pharmacovigilance providers, and regulatory consultancies. Its key differentiators are its integrated three-pillar service model, deep therapeutic focus on complex areas like oncology, and a culture tailored to the needs of agile biotech sponsors.